Taysha Gene Therapies, Inc. TSHA Proceeds From Issuance Of Common Stock Pursuant To At The Market Offering Net Of Sales Commissions And Other Offering Costs
Proceeds From Issuance Of Common Stock Pursuant To At The Market Offering Net Of Sales Commissions And Other Offering Costs at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept tsha:ProceedsFromIssuanceOfCommonStockPursuantToAtTheMarketOfferingNetOfSalesCommissionsAndOtherOfferingCosts.
The official record: Taysha Gene Therapies, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s proceeds from issuance of common stock pursuant to at the market offering net of sales commissions and other offering costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s proceeds from issuance of common stock pursuant to at the market offering net of sales commissions and other offering costs?
- Taysha Gene Therapies, Inc. (TSHA) reported proceeds from issuance of common stock pursuant to at the market offering net of sales commissions and other offering costs of $12.11M in Q4 2025.
- What does proceeds from issuance of common stock pursuant to at the market offering net of sales commissions and other offering costs mean?
- This captures the net cash proceeds from 'at-the-market' (ATM) equity offerings, where shares are sold incrementally into the public market over time. This mechanism provides the company with flexible, ongoing access to capital to support operational runway. It is a common tool for biotech firms to manage liquidity without the volatility of large, discrete public offerings.